Gel4Med

Gel4Med is a commercial-stage medical biomaterials company headquartered in Brighton, Massachusetts, in the United States. Founded out of the Harvard Innovation Labs at Harvard University, the company describes itself as using bioinspiration and materials engineering to solve significant challenges in medicine. Its proprietary, patented Smart Materials Platform™ (SMP™) is a bioengineering approach for developing therapeutics and devices intended to address a wide range of clinical needs. Gel4Med's lead asset is G4Derm™ / G4Derm™ Plus, a flowable biomimetic matrix directed at wound care and surgical reconstruction. In October 2023 the company received its first FDA 510(k) market clearance for G4Derm™ / G4Derm™ Plus. The company also offers Suprello™ Wound Matrix, described as a next-generation, peptide-based wound matrix engineered to support secure closure and healing in high-risk surgical cases. Both G4Derm™ Plus and Suprello™ are supplied as 2 ml units and are available in the USA only. The company is led by co-founder and CEO Manav Mehta, PhD, and has assembled a team of scientists and product-development specialists in biomaterials, cell and tissue biology, and microbiology. Its advisory board includes academic and industry figures such as Darrin Poachan of the University of Delaware, Joel Schneider of the National Institutes of Health, and Kenneth Burhop, former Chief Scientific Officer of Integra Life Sciences. Investors include Lindy Fishburne of Breakout Ventures and Priya Yadav of MassVentures. Gel4Med maintains its headquarters in Brighton, Massachusetts, and an R&D laboratory at M2D2 at UMass Lowell in Lowell, Massachusetts. The company has also announced collaborations, including funded work with the University of Miami around novel treatments for spinal cord injury, and states that it has been awarded significant funding. It serves both non-government and government customers, the latter through a partnership with a federal contractor.

Gel4Med was founded out of the Harvard Innovation Labs at Harvard University, according to the company's own account. It describes itself as a commercial-stage company that uses bioinspiration and materials engineering to solve significant challenges in medicine. The company's core technology is its proprietary, patented Smart Materials Platform™ (SMP™), a bioengineering approach for developing therapeutics and devices to address a wide range of clinical needs. Gel4Med's lead asset, G4Derm™ / G4Derm™ Plus, is directed at wound care and surgical reconstruction. In October 2023, the company received its first FDA 510(k) market clearance on G4Derm™ / G4Derm™ Plus. The company subsequently announced that the FDA had granted 510(k) clearance for its first biosynthetic matrix products, including G4Derm™ Plus and Suprello™. Suprello™ Wound Matrix is described as a next-generation, peptide-based wound matrix engineered to support secure closure and healing in high-risk surgical cases. The company is headquartered at 1660 Soldiers Field Road, STE 7, #1063, Brighton, MA 02135, and maintains an R&D laboratory at M2D2 at UMass Lowell, 110 Canal St, 4th Floor, Lowell, MA 01852. It is led by co-founder and CEO Manav Mehta, PhD, and has built a team of scientists and specialists in biomaterials, cell and tissue biology, microbiology, product development, quality, and clinical operations. Its advisory board includes Darrin Poachan, PhD, Chair of the Department of Materials Science & Engineering at the University of Delaware; Joel Schneider, PhD, Chief of the Chemical Biology Laboratory at the National Institutes of Health; and Kenneth Burhop, PhD, former Chief Scientific Officer of Integra Life Sciences. Investors listed by the company include Lindy Fishburne, MBA, Managing Partner at Breakout Ventures, and Priya Yadav, MS, Vice President of Investments at MassVentures. Gel4Med has announced collaborations and funding, including a funded collaboration with the University of Miami to innovate around novel treatments for spinal cord injury, and states that it has been awarded significant funding. The company sells G4Derm™ Plus and Suprello™ as 2 ml units available in the USA only, and serves government customers through a partnership with a top federal contractor, with DUNS 079722830, CAGE 7ASRO, and NAICS 339113.

• Founded out of the Harvard Innovation Labs at Harvard University

• Received first FDA 510(k) market clearance on G4Derm™ / G4Derm™ Plus

• FDA granted 510(k) clearance for first biosynthetic matrix products, including G4Derm™ Plus and Suprello™

• Announced funded collaboration with the University of Miami on novel treatments for spinal cord injury

Commercial-stage biomaterials company developing bioinspired medical solutions through its patented Smart Materials Platform™ to address unmet clinical needs in wound care and surgical reconstruction.

• G4Derm™ / G4Derm™ Plus

  Lead asset directed at wound care and surgical reconstruction; a flowable biomimetic matrix derived from the Smart Materials Platform™; received FDA 510(k) clearance in October 2023; supplied as a 2 ml unit (SKU G4M200M) available in the USA only.

• Suprello™ Wound Matrix

  A next-generation, peptide-based wound matrix engineered to support secure closure and healing in high-risk surgical cases; supplied as a 2 ml unit (SKU G4M100M) available in the USA only.

• Smart Materials Platform™ (SMP™)

  Gel4Med's proprietary, patented bioengineering approach for developing therapeutics and devices to address a wide range of clinical needs.

1. 1Gel4Med | Leading Innovation in Bioinspired Medical Solutionsgelformed.com
2. 2Order G4Derm™ Plus Advanced Wound System | Gel4Medgelformed.com
3. 3About Us | Gel4Med: Pioneering Advanced Medical Solutionsgelformed.com
4. 4Gel4Med (United States) - Wikidatawikidata.org